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Abstract
AIM: To investigate whether assigning young, healthy 
and motivated lay volunteer partners (“buddies”) to 
adolescents with type 2 diabetes improves hemoglobin 
A1c (HbA1c). 
METHODS: Adolescents with type 2 diabetes were 
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Randomized Clinical Trial
randomized to partnering with a “buddy” or to conve-
ntional treatment. During the initial screening visit, 
which coincided with a routine outpatient diabetes 
clinic visit, patients with type 2 diabetes underwent 
a physical examination, detailed medical history, 
laboratory measurement of HbA1c, and completed two 
questionnaires (Pediatric Quality of Life Inventory and 
Children’s Depression Inventory)  to assess their overall 
quality of life and the presence of depressive symptoms. 
Patients were then randomized to the intervention (the 
buddy system) or conventional treatment (standard 
care). All patients were scheduled to return for follow-
up at 3- and 6-mo after their initial visit. HbA1c was 
determined at all visits (i.e. , at screening and at the 
3- and 6-mo follow-up visits) and quality of life and 
depressive symptoms were evaluated at the screening 
visit and were reassessed at the 6-mo visit. 
RESULTS: Ten adolescents, recruited from a pool of 
approximately 200 adolescents, enrolled over a two-
year time period, leading to premature termination of 
the study. In contrast, we easily recruited motivated lay 
volunteers. We found no change in HbA1c from the initial 
to the 6-mo visit in either group, yet our small sample 
size limited systematic assessment of this outcome. 
Participants repeatedly missed clinic appointments, failed 
to conduct self-glucose-monitoring and rarely brought 
their glucometers to clinic visits. Total quality of life scores 
(72.6 ± 6.06) at screening were similar to previously 
reported scores in adolescents with type 2 diabetes (75.7 
± 15.0) and lower than scores reported in normal-weight 
(81.2 ± 0.9), overweight (83.5 ± 1.8), and obese youths 
without diabetes (78.5 ± 1.8) or in adolescents with 
type 1 diabetes (80.5 ± 13.1). Among adolescents who 
returned for their 6-mo visit, there were no differences 
in total quality of life scores (70.2 ± 9.18) between 
screening and follow-up.
CONCLUSION: Our approach, effective in adults with 
type 2 diabetes, was unsuccessful among adolescents 
and emphasizes the need for innovative strategies for 
diabetes treatment in adolescent patients. 
Key words: Diabetes mellitus type 2; Quality of life; 
Adolescent; Hemoglobin A1c; Social support
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Our manuscript details results and challenges 
during a simple psychosocial intervention trial where 
young, healthy and motivated lay volunteer partners 
(“buddies”) were assigned to adolescents with type 2 
diabetes. We experienced difficulty in the recruitment 
and retention of adolescent patients, which ultimately 
led to premature study termination. Despite our negative 
findings, our manuscript calls attention to the fact that 
psychosocial approaches shown to be effective in adults 
with type 2 diabetes may not translate in adolescent 
patients and conveys a unique and important message 
to other investigators who may wish to attempt similar 
interventions among adolescents with type 2 diabetes. 
Sylvetsky AC, Nandagopal R, Nguyen TT, Abegg MR, Nagarur 
M, Kaplowitz P, Rother KI. Buddy Study: Partners for better health 
in adolescents with type 2 diabetes. World J Diabetes 2015; 6(18): 
1355-1362  Available from: URL: http://www.wjgnet.com/1948-9358/
full/v6/i18/1355.htm  DOI: http://dx.doi.org/10.4239/wjd.v6.i18.1355
INTRODUCTION
Type 2 diabetes in adolescence is generally associated 
with obesity, a positive family history of type 2 diabetes, 
and a low-income minority background[1,2]. Beta cell 
failure in adolescents progresses more rapidly than in 
adults and responds less to medical treatment as was 
shown in the recently completed TODAY trial (Treatment 
Options for Type 2 Diabetes in Adolescents and Youth)[3]. 
Because the progression of diabetes.... and ending 
with: Critical in this patient population. This trial is the 
only existing large-scale intervention study in youth 
with type 2 diabetes, which is in part due to difficult 
recruitment of these individuals[4]. Obesity related 
co-morbidities together with potentially long-lasting 
diabetes, dramatically increase the risk of macrovascular 
disease later in life. Microvascular complications including 
peripheral neuropathy and retinopathy have also been 
shown to occur, even at such a young age[5,6]. 
Guidelines from the American Academy of Pediatrics 
recommend that clinicians combine weight management 
counseling focused on improving diet, increasing physical 
activity, and reducing television and computer screen time 
along with metformin administration at the time of diabetes 
diagnosis[1]. It is well known, however, that adolescent 
patients[7,8] and those from low-income minority groups[8] 
often have difficulties in adhering to these recommended 
life-style changes and medical treatments. Even among 
adults who historically exhibit better compliance compared 
to adolescents, non-adherence is one of the most im-
portant barriers to successful treatment[9]. Psychosocial 
interventions in adults with type 2 diabetes have shown 
promise in increasing adherence to treatment[10-15] and/or 
improving hemoglobin A1c (HbA1c)[16-22]. For example, two 
interventions[16,17], in which adults with type 2 diabetes were 
paired with age- and gender- matched lay peer mentors 
(who also had diabetes), were effective in improving 
blood glucose control. Other interventions involving 
diabetes self-management education conducted in a 
group setting[18-21] have also led to better glycemia, while 
diabetes support delivered via online[23], telephone[10,14,22], 
or text messaging[15] programs has improved treatment 
adherence. Educational and psychosocial interventions 
have also been effective in improving both HbA1c and 
psychological health in adolescents with type 1 dia-
betes[24], yet to our knowledge, similar studies have not 
been conducted in adolescents with type 2 diabetes. The 
objectives of this study were to test whether a low-cost 
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intervention in which a young, healthy and motivated lay 
volunteer partner is assigned to an adolescent with type 
2 diabetes, can improve HbA1c, adherence to treatment, 
and quality of life. 
MATERIALS AND METHODS
Participants
Adolescents (aged 12-20 years) with type 2 diabetes 
received information about the “Buddy Study” from 
their pediatric endocrinologists during routine outpatient 
diabetes clinic visits at Children’s National Medical 
Center (CNMC) in Washington, DC and at the National 
Institutes of Health Clinical Center (NIH CC) in Bethesda, 
MD. Whenever possible, interested patients and their 
caregivers also met with a trained research assistant to 
learn more about the study immediately after their clinic 
appointment. Recruitment occurred between January 2010 
and November 2011. The diagnosis of type 2 diabetes 
was based on their primary physician’s assessment[25]. 
For study inclusion, patients had to have a documented 
HbA1c ≥ 7% (≥ 53 mmol/mol). Individuals were 
excluded if they had a significant comorbidity or 
psychological disorder that would interfere with their 
ability to participate (e.g., a history of violent behavior, 
which could pose a risk to the lay volunteers), or if they 
were pregnant or planning to become pregnant within six 
months of the initial visit. Informed written consent and 
assent (in individuals < 18 years of age) were obtained 
prior to enrollment. The study protocol, consents and 
all study procedures were approved by the Institutional 
Review Boards at the CNMC and the NIH CC and were in 
accordance with the Declaration of Helsinki.
Lay volunteers, or “buddies”, between 18 and 25 years 
of age were recruited from a pool of research assistants 
at the National Institutes of Health (NIH). Volunteers were 
screened and selected by the study physicians and were 
matched by gender with an adolescent patient. This was 
deemed necessary to facilitate the home visits. Further 
matching was not conducted (e.g., by race, ethnicity, 
body mass index or education) for practical reasons due 
to the known demographic characteristics of the NIH 
research assistants. The lay volunteers did not have type 
2 diabetes. All volunteers underwent standardized training 
and criminal background check in collaboration with the 
NIH Volunteer Services office and received specific training 
about the management of home visits from a NIH social 
worker. 
Study design
The “Buddy Study” was a randomized, parallel-group 
study of six months duration conducted at CNMC in 
Washington, DC and the NIH CC in Bethesda, MD. The 
NIH CC depends on physician-referred or self-referred 
research participants while CNMC is a tertiary medical 
center in which approximately 120 youths with type 
2 diabetes (new and established disease) are seen 
annually. During the initial screening visit, which coincided 
with a routine outpatient diabetes clinic visit, patients 
with type 2 diabetes underwent a physical examination, 
detailed medical history, laboratory measurement of 
HbA1c, and completed two questionnaires (Pediatric 
Quality of Life Inventory (PedsQL)[26] and Children’s 
Depression Inventory (CDI)[27] to assess their overall 
quality of life and the presence of depressive symptoms. 
Patients were then randomized to the intervention (the 
buddy system) or conventional treatment (standard 
care). All patients were scheduled to return for follow-
up at 3- and 6-mo after their initial visit. Participants 
received modest financial compensation for their time 
and inconvenience ($100).
The intervention arm (buddy group) was designed 
to receive weekly telephone calls from their assigned 
buddies and one home visit per month (lasting 30-60 min) 
to encourage “bonding” in a comfortable environment. 
Meetings between patients and buddies took place 
at locations of the patient’s choice (preferably at their 
home), and contacts were made via phone, cell phone, 
and e-mail. Alternative buddy-patient meeting places 
included schools, coffee-shops, or libraries chosen by 
both parties at a mutually convenient time if home 
visits were declined by the participant or his/her family. 
Buddies were encouraged to not only ask the patient 
about diabetes management and provide telephone 
reminders for diabetes follow-up appointments, but also 
to discuss the patient’s home and social life in order to 
promote a nurturing and motivating relationship. Buddies 
were strictly prohibited from providing medical advice 
and were told to contact the Principal Investigator should 
a need for medical advice arise. Details of the study 
procedures are shown in Figure 1. 
Measures
The primary outcome was the effect of the intervention 
on hemoglobin A1c (HbA1c), which was measured using 
the Siemens-Bayer DCA 2000+. At all visits, HbA1c, 
height and weight were measured, and body mass 
index (BMI) was calculated. Change in HbA1c for the 
intervention arm (buddy group) vs the conventional 
treatment group was compared using the Student’s t-test. 
Socio-demographic and clinically relevant information 
including self-reported race/ethnicity, family history of 
diabetes and patient medication use was also collected. 
All clinical information and laboratory data were compiled 
in the eSphere Clinical Trials Data Management System 
(Espirit Health, Chicago, IL).
Adolescents’ quality of life and depressive symptoms 
were evaluated at the screening visit and were reassessed 
at the 6-mo visit using the PedsQL[26], a validated 23-item 
questionnaire to assess physical, emotional, social and 
school functioning and the CDI[27], a validated 27-item 
self-report measure designed to determine the extent and 
severity of depressive symptoms in children (cut-off for 
depression score ≥ 13), respectively. 
RESULTS
Forty adolescents with type 2 diabetes were screened 
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and eligible. As shown in Figure 1, ten adolescents 
were enrolled in the “Buddy Study”, of whom five were 
randomized to the intervention arm and paired with 
a buddy. Five adolescents (three randomized to the 
buddy group and two to the conventional arm) returned 
to the clinic for both 3- and 6-mo follow-up visits. 
Baseline characteristics and a brief case description for 
each adolescent are shown in Table 1. The majority 
of our study participants were non-Hispanic Black, 
obese (mean BMI 37.0 ± 13.7 kg/m2) and all but one 
had a positive family history for type 2 diabetes. The 
average age was 15.8 ± 2.0 years, diabetes duration 
22.1 ± 20.4 mo, and the starting HbA1c was 10.6% ± 
3.0% (92.4 mmol/mol) with all participants receiving 
metformin and four of ten receiving insulin. Diabetes 
and obesity related comorbidities were documented in 
50%, but not all patients had undergone screening for 
retinopathy. 
While early study termination prevented us from 
systematically assessing the primary outcome, HbA1c 
did not improve at 6 mo compared to screening in 
either group. Total quality of life scores (72.6 ± 6.06) 
at screening were similar to previously reported scores 
in adolescents with type 2 diabetes (75.7 ± 15.0)[28] 
and lower than scores reported in normal-weight (81.2 
± 0.9), overweight (83.5 ± 1.8), and obese youths 
without diabetes (78.5 ± 1.8)[29] or in adolescents with 
type 1 diabetes (80.5 ± 13.1)[28]. Among adolescents 
who returned for their 6-month visit, there were no 
differences in total quality of life scores (70.2 ± 9.18) 
between screening and follow-up. Using the CDI criteria 
for depression, three adolescents were depressed but 
none was suicidal at screening. No participant received 
treatment with antidepressants. 
The average age of our lay volunteers (buddies) was 
23.0 ± 0.71 years and four of the five volunteers were 
female, as adolescent patients and buddies were gender 
matched. The four female buddies all self-identified as 
non-Hispanic White, while the one male buddy self-
identified as Asian. 
DISCUSSION
In this study, we aimed to test whether a “buddy” 
intervention in adolescent patients with type 2 diabetes 
was effective in improving HbA1c, adherence to 
treatment, and quality of life. This particular approach 
has been shown to be promising in adults with type 
2 diabetes and similar educational and psychosocial 
interventions have been successful in adolescents 
with type 1 diabetes[24], but has not been tested in 
adolescents[10,11]. 
Recruitment of adolescents with type 2 diabetes was 
difficult. Only ten adolescents, recruited from a pool 
of approximately 200 outpatients at CNMC, enrolled 
over a two-year time period, which led to premature 
termination of the study. In contrast, we easily recruited 
motivated lay volunteers. We found no change in HbA1c 
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Screening: 
Patients with type 2 diabetes, 
Age 12-20 year and HbA1c ≥ 7% 
(53 mmol/mol) 
(n  = 40)
Declined participation (n  = 30)
Consent and 
randomization (n  = 10)
“Buddy” Group 
Weekly phone calls or messaging
1 home visit per month (n  = 5)
Conventional arm 
Standard care for T2DM
(n  = 5)
n  = 1 lost to follow-up
3 mo visit in diabetes clinic: 
HbA1c, meter downloads (n  = 4)
3-mo visit in diabetes clinic: 
HbA1c, meter downloads (n  = 3)
6 mo visit in diabetes clinic: 
HbA1c, meter downloads (n  = 3)
6 mo visit in diabetes clinic: 
HbA1c, meter downloads (n  = 3)
n  = 1 did not attend
n  = 1 lost to follow-up
n  = 1 returned for final 
visit
n  = 1 lost to 
follow-up
n  = 1 lost to 
follow-up
Figure 1  Forty adolescents with type 2 diabetes were screened and eligible for participation in the “Buddy Study”. Ten adolescents were enrolled in the study, of 
whom five were randomized to the intervention arm and paired with a buddy. The remaining five adolescents were randomized to the standard care group and were not 
paired with a buddy. Five adolescents (three randomized to the buddy group and two to the conventional arm) returned to the clinic for both 3- and 6-mo follow-up visits 
and six adolescents completed the six month study. HbA1C:  Hemoglobin A1C.
from the initial to the 6-mo visit in either group, yet our 
small sample size limited systematic assessment of this 
outcome. The early termination of the “Buddy Study” was 
particularly disappointing, as the scientific community 
supported the “Buddy Study” as an important and 
worthwhile trial. One team member (RN) was awarded 
the 2010 Endocrine Fellows Foundation Marilyn Fishman 
Grant for Diabetes Research for designing the protocol. 
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24.1 Yes None Control group. Poor medication and dietary 
compliance. Frequently consumed sugar-
sweetened beverages and sneaked food late at 
night. Mother attributed behavior to depression 
and stress from a recent custody battle. Significant 
behavioral issues in school
2 19 42 Female Non-hispanic 
white
Metformin 39.5 Yes Pre-hypertension Buddy group. Fairly compliant with oral 
medications but noncompliant with insulin 
administration or blood glucose monitoring. 
Improved dietary habits but not exercise
3 18 48 Male Non-hispanic 
black
Metformin 39.5 Yes Cataract Control group. History of anorexia. Complicated 
relationship with food. Has developmental delay 
and is in special education classes at school. 
Motivated to change lifestyle. Poor compliance 
with medication and glucose monitoring
4 14 11 Female Non-hispanic 
black
Metformin 42.9 Yes Hypertension Buddy group. Poor compliance with medication. 
Skipped breakfast and lunch. Snacked excessively 
after school and in the evening. Mother had 
limited ability to supervise because she was not 
often home
5 13 5 Female Non-hispanic 
black
Metformin 71.5 Yes Microalbuminuria Control group. First seen in clinic for obesity 
at age 6, then lost to follow-up for 7 yr prior 
to entering study. Gained 109.4 kg during this 
period. Discontinued sodas and juices and 
signed up for an exercise class, however, was 
subsequently lost to follow-up
6 14 13 Female Hispanic Metformin 34.2 Yes None Buddy group. Unmotivated to initiate behavior 
change and non-compliant with medication 
and blood glucose monitoring. Unresponsive 
to communication attempts by assigned buddy. 
Did not report any exercise. No attempt to alter 
dietary habits. Lost to follow-up
7 16 3 Male Asian/pacific 
islander
Metformin 32.7 Yes None Control group. Very motivated and successful at 
lifestyle modification. Reverted to poor diet and 
exercise following family emergency. Medications 
subsequently re-initiated but compliance 
remained poor




24.7 Yes None Buddy group. Poor medication compliance. 
No exercise despite parental encouragement. 
Removed sugar-sweetened beverages from diet 
but struggled with portion control. Improved 
compliance with medication regimen following 
hospitalization




34.3 Yes Microalbuminuria 
hypertension
Buddy group. Compliant with medication but not 
glucose monitoring or diet. Mother encouraged 
portion control with little success. Patient had 
developmental delay but appeared to understand 
importance of lifestyle modification and was 
motivated. However, lost to follow-up




26.8 No None Control group. Poor compliance with medication 


















BMI: Body mass index; T2DM: Type 2 diabetes mellitus.
Furthermore, the study was promoted by the Scientific 
Director of the National Institute of Diabetes, Digestive, 
and Kidney Diseases (NIDDK) as part of the “Healthy 
Moments” radio series[30]. Our experience may serve to 
caution other investigators in attempting to implement 
similar strategies for diabetes management among 
adolescents. It is possible that others have conducted 
but not reported such experience, because bias against 
submission and publication of negative study findings is 
problematic in the medical literature[31]. Our seemingly 
“unexciting” findings convey a unique message for other 
investigators[32]. 
Challenges in the recruitment of adolescents into 
clinical research protocols have been well described[4,33,34]. 
Similar to most adolescents, these youths with type 
2 diabetes strive to fit in with peer norms and wish to 
conform to their perception of what is “normal”, posing 
a barrier to participation in research studies[35]. Even in 
the TODAY trial, the largest and most resource-intensive 
randomized, controlled intervention trial to be conducted 
in adolescents with type 2 diabetes[36], recruitment was 
difficult and the projected recruitment period had to be 
extended by two years[37]. This emphasizes the need for 
improved recruitment strategies specifically targeting 
adolescents.
As reflected in our cohort, data from both TODAY and 
the “Search for Diabetes in Youth” (SEARCH) trials[37,38] 
have demonstrated that type 2 diabetes disproportionately 
affects youth from racial/ethnic minority groups. In 
addition to facing difficulties with recruitment of individuals 
from minority groups[39,40] and younger age groups[41] 
into chronic disease prevention and treatment programs, 
epidemiologic data suggest that poor blood glucose 
control is most prevalent among these subgroups[38]. 
In accordance with the emerging field of molecular 
pathological epidemiology (MPE)[42], complex diseases 
including type 2 diabetes may comprise various subtypes 
involving heterogeneous subpopulations. Because the 
etiology underlying type 2 diabetes is multifactorial, 
different disease subtypes may be associated with different 
biological, social, and environmental determinants and 
diverse natural histories. Thus, diabetes may progress at 
different rates and respond differently to interventions and 
treatments in certain individuals[43], as we observed in our 
study of adolescents with type 2 diabetes. 
We observed low self-reported quality of life and frequent 
depressive symptoms, both of which are associated with 
exacerbated metabolic disturbance and poor glycemia 
control[44]. Given the high rates of treatment failure on 
metformin among adolescents[36], the implementation of a 
buddy system to encourage and sustain lifestyle changes 
and improve psychosocial health was a seemingly hopeful 
undertaking. However, even the best-designed programs 
cannot be effective if adolescents do not participate[45] nor 
can they be successful if adolescents who do participate are 
not compliant with medications and study requirements. 
This is exemplified by the high frequency of missed clinic 
appointments, continued failure to conduct self-glucose 
monitoring, and widespread non-compliance with medication 
and lifestyle recommendations. Of note, the “Buddy Study” 
was designed to place the burden and inconvenience of study 
participation on the research team rather than on the study 
participants (e.g., meetings between patients and buddies 
took place at locations of the patient’s choice, and contacts 
were made via phone, cell phone, and e-mail). 
Several modifications to our study may have facilitated 
improved enrollment and/or enhanced compliance with 
treatment recommendations. First, pairing adolescents 
with peer volunteers who themselves have type 2 
diabetes[16] and had successfully improved their glycemia[46] 
or with lay volunteers of the same race/ethnicity and/or 
socio-economic status[46] may have been more effective 
in building trust between adolescents and their buddies[47] 
and generating interest in study participation. Approaching 
adolescents at the time of their diabetes diagnosis may 
also have been helpful, as early intervention has shown 
promise in chronic disease management[48]. Future efforts 
to raise adolescent understanding of the physiology of 
type 2 diabetes may also be worthwhile in enhancing 
participation[49]. 
Another hurdle is the limited time a practicing phy-
sician can afford to spend on clinical trial recruitment. 
In our study, several patients were not informed about 
the study by the treating physician because the medical, 
psychological and/or psychosocial situation was so 
complicated that no further topics could be discussed in 
the short time of the clinic visit. Though we attempted to 
have a research assistant present at all times, logistically 
this was not feasible.
In summary, our study provides insight into the 
difficulties of translating an intervention effective in 
adults with type 2 diabetes into a successful approach 
in adolescents with the same condition. The challenges 
faced during the “Buddy Study” may serve as a cau-
tion to other investigators attempting to implement 
similar strategies for diabetes management among 
adolescents. Our findings emphasize the urgent need 
for improved recruitment strategies specifically targeting 
adolescents.
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increase the risk of micro-and macro-vascular complications at a young age. 
Research frontiers
Psychosocial interventions in adults with type 2 diabetes and in youth with 
type 1 diabetes have shown promise in increasing adherence to treatment, 
improving psychological health in adolescents with type 1 diabetes, and/or 
lowering hemoglobin A1c (HbA1c), yet similar studies have not been conducted 
in adolescents with type 2 diabetes.
Innovations and breakthroughs
The study tested an intervention shown to be effective in adults with type 2 
diabetes in a cohort of adolescents with the same condition. The findings 
provide insight into the difficulties of translating an intervention effective in 
adults with type 2 diabetes into a successful approach in adolescents and 
highlight the need for innovative strategies to improve recruitment and retention 
of adolescents with type 2 diabetes into diabetes treatment programs. 
Applications
Given the recruitment challenges faced, the authors’ study may serve as 
a caution to other investigators attempting to implement similar strategies 
for diabetes management among adolescents. Based on their experience, 
additional practical considerations for designing interventions in adolescents 
may include pairing adolescents with peer volunteers who themselves have 
type 2 diabetes and had successfully improved their glycemia or with lay 
volunteers of the same race/ethnicity and/or socio-economic status. In addition, 
future efforts to raise adolescent understanding of the physiology of type 2 
diabetes may also be worthwhile in motivating adolescents to participate in 
diabetes treatment programs.
Terminology
While they expect that the terminology in our manuscript is familiar to most 
readers, they wish to define two critical terms mentioned repeatedly in the 
manuscript: psychosocial intervention and (HbA1c). Psychosocial interventions 
are interventions that are designed to change behavior and have a direct focus 
on a person’s social environment including interpersonal interactions and social 
support. This is in contrast to a medical approach, in which participants are 
prescribed medication or assigned to a specific diet. (HbA1c) is a commonly 
used indicator of glycemic control over a 3-4 mo period. (HbA1c) measures 
the percentage of one’s hemoglobin (a protein in red blood cells) that is 
glycosylated or in other words, has sugar attached to it. 
Peer-review
The study is an interesting analysis about the insight into the difficulties 
of translating an intervention effective in adults with type 2 diabetes into a 
successful approach in adolescents with the same disease.
REFERENCES
1 Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer 
T, Shiffman RN, Springer SC, Thaker VV, Anderson M, Spann 
SJ, Flinn SK. Management of newly diagnosed type 2 Diabetes 
Mellitus (T2DM) in children and adolescents. Pediatrics 2013; 
131: 364-382 [PMID: 23359574 DOI: 10.1542/peds.2012-3494]
2 D’Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology 
and pathophysiology. Diabetes Care 2011; 34 Suppl 2: S161-S165 
[PMID: 21525449 DOI: 10.2337/dc11-s212]
3 Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, 
Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A 
clinical trial to maintain glycemic control in youth with type 2 
diabetes. N Engl J Med 2012; 366: 2247-2256 [PMID: 22540912 
DOI: 10.1056/NEJMoa1109333]
4 Nguyen TT, Jayadeva V, Cizza G, Brown RJ, Nandagopal R, 
Rodriguez LM, Rother KI. Challenging recruitment of youth with 
type 2 diabetes into clinical trials. J Adolesc Health 2014; 54: 
247-254 [PMID: 24161585 DOI: 10.1016/j.jadohealth.2013.08.01
7]
5 Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, 
Pettitt DJ, Saydah S, Pihoker C, Standiford DA, Rodriguez BL, 
Pop-Busui R, Feldman EL. Peripheral neuropathy in adolescents 
and young adults with type 1 and type 2 diabetes from the 
SEARCH for Diabetes in Youth follow-up cohort: a pilot study. 
Diabetes Care 2013; 36: 3903-3908 [PMID: 24144652 DOI: 
10.2337/dc13-1213]
6 Today Study Group. Retinopathy in youth with type 2 diabetes 
participating in the TODAY clinical trial. Diabetes Care 2013; 36: 
1772-1774 [PMID: 23704677 DOI: 10.2337/dc12-2387]
7 Barnes NS, White PC, Hutchison MR. Time to failure of 
oral therapy in children with type 2 diabetes: a single center 
retrospective chart review. Pediatr Diabetes 2012; 13: 578-582 
[PMID: 22646303 DOI: 10.1111/j.1399-5448.2012.00873.x]
8 DiMatteo MR. Variations in patients’ adherence to medical 
recommendations: a quantitative review of 50 years of research. 
Med Care 2004; 42: 200-209 [PMID: 15076819]
9 Kirkman MS, Herrera V, Hawk G, Fonseca V, Schmidttdiel 
JA, Herman WH, Aubert RE. Determinants of Non-Adherence 
to Diabetes Medications (abstract). In ADA Scientific Sessions, 
Chicago, IL, June 21-25, 2013
10 Lorig K, Ritter PL, Villa FJ, Armas J. Community-based peer-led 
diabetes self-management: a randomized trial. Diabetes Educ 2009; 
35: 641-651 [PMID: 19407333 DOI: 10.1177/0145721709335006]
11 Keyserling TC, Samuel-Hodge CD, Ammerman AS, Ainsworth 
BE, Henríquez-Roldán CF, Elasy TA, Skelly AH, Johnston LF, 
Bangdiwala SI. A randomized trial of an intervention to improve 
self-care behaviors of African-American women with type 2 
diabetes: impact on physical activity. Diabetes Care 2002; 25: 
1576-1583 [PMID: 12196430]
12 Allen NA, Fain JA, Braun B, Chipkin SR. Continuous glucose 
monitoring counseling improves physical activity behaviors of 
individuals with type 2 diabetes: A randomized clinical trial. 
Diabetes Res Clin Pract 2008; 80: 371-379 [PMID: 18304674 
DOI: 10.1016/j.diabres.2008.01.006]
13 Babamoto KS, Sey KA, Camilleri AJ, Karlan VJ, Catalasan 
J, Morisky DE. Improving diabetes care and health measures 
among hispanics using community health workers: results from a 
randomized controlled trial. Health Educ Behav 2009; 36: 113-126 
[PMID: 19188371 DOI: 10.1177/1090198108325911]
14 Rotheram-Borus MJ, Tomlinson M, Gwegwe M, Comulada WS, 
Kaufman N, Keim M. Diabetes buddies: peer support through a 
mobile phone buddy system. Diabetes Educ 2012; 38: 357-365 
[PMID: 22546740 DOI: 10.1177/0145721712444617]
15 Vervloet M, van Dijk L, Santen-Reestman J, van Vlijmen B, van 
Wingerden P, Bouvy ML, de Bakker DH. SMS reminders improve 
adherence to oral medication in type 2 diabetes patients who are 
real time electronically monitored. Int J Med Inform 2012; 81: 
594-604 [PMID: 22652012 DOI: 10.1016/j.ijmedinf.2012.05.005]
16 Heisler M, Vijan S, Makki F, Piette JD. Diabetes control 
with reciprocal peer support versus nurse care management: a 
randomized trial. Ann Intern Med 2010; 153: 507-515 [PMID: 
20956707 DOI: 10.7326/0003-4819-153-8-201010190-00007]
17 Long JA. “Buddy system’’ of peer mentors may help control 
diabetes. LDI Issue Brief 2012; 17: 1-4 [PMID: 22451999]
18 Thom DH, Ghorob A, Hessler D, De Vore D, Chen E, Bodenheimer 
TA. Impact of peer health coaching on glycemic control in low-
income patients with diabetes: a randomized controlled trial. Ann 
Fam Med 2013; 11: 137-144 [PMID: 23508600 DOI: 10.1370/
afm.1443]
19 Rosal MC, Olendzki B, Reed GW, Gumieniak O, Scavron J, 
Ockene I. Diabetes self-management among low-income Spanish-
speaking patients: a pilot study. Ann Behav Med 2005; 29: 225-235 
[PMID: 15946117]
20 Deakin TA, Cade JE, Williams R, Greenwood DC. Structured 
patient education: the diabetes X-PERT Programme makes a 
difference. Diabet Med 2006; 23: 944-954 [PMID: 16922700 DOI: 
10.1111/j.1464-5491.2006.01906.x]
21 Kulzer B, Hermanns N, Reinecker H, Haak T. Effects of self-
management training in Type 2 diabetes: a randomized, prospective 
trial. Diabet Med 2007; 24: 415-423 [PMID: 17298590 DOI: 
1361 December 25, 2015|Volume 6|Issue 18|WJD|www.wjgnet.com
Sylvetsky AC et al . Buddies for adolescents with diabetes
10.1111/j.1464-5491.2007.02089.x]
22 Walker EA, Schecter CB, Gonzalez JS, Silver LD. Results of the 
Bronx A1c Telephonic Behavioral Intervention Study In American 
Diabetes Association Annual Meeting. Chicago, IL, 2013
23 Lorig K, Ritter PL, Laurent DD, Plant K, Green M, Jernigan VB, 
Case S. Online diabetes self-management program: a randomized 
study. Diabetes Care 2010; 33: 1275-1281 [PMID: 20299481 DOI: 
10.2337/dc09-2153.2875437]
24 Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft 
D, Kimber A, Shaw K, Walker J. Effects of educational and 
psychosocial interventions for adolescents with diabetes mellitus: 
a systematic review. Health Technol Assess 2001; 5: 1-79 [PMID: 
11319990]
25 Search Study Group. SEARCH for Diabetes in Youth: a 
multicenter study of the prevalence, incidence and classification of 
diabetes mellitus in youth. Control Clin Trials 2004; 25: 458-471 
[PMID: 15465616 DOI: 10.1016/j.cct.2004.08.002]
26 Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity 
of the Pediatric Quality of Life Inventory version 4.0 generic core 
scales in healthy and patient populations. Med Care 2001; 39: 
800-812 [PMID: 11468499]
27 Kovacs M. The Children’s Depression Inventory (CDI) technical 
manual. Toronto: ON: Multi-Health Systems, 2003
28 Hilliard ME, Lawrence JM, Modi AC, Anderson A, Crume T, 
Dolan LM, Merchant AT, Yi-Frazier JP, Hood KK. Identification 
of minimal clinically important difference scores of the PedsQL 
in children, adolescents, and young adults with type 1 and type 2 
diabetes. Diabetes Care 2013; 36: 1891-1897 [PMID: 23340884 
DOI: 10.2337/dc12-1708.3687260]
29 Gopinath B, Baur LA, Burlutsky G, Mitchell P. Adiposity 
adversely influences quality of life among adolescents. J Adolesc 
Health 2013; 52: 649-653 [PMID: 23425948 DOI: 10.1016/j.jadoh
ealth.2012.11.010]
30 NIDDK. Is Everything Better with a Friend? In Healthy Moments. 
Bethesda, MD: National Institutes of Health, 2011
31 Olson CM, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan 
JW, Zhu Q, Reiling J, Pace B. Publication bias in editorial decision 
making. JAMA 2002; 287: 2825-2828 [PMID: 12038924]
32 Connor JT. Positive reasons for publishing negative findings. Am 
J Gastroenterol 2008; 103: 2181-2183 [PMID: 18671812 DOI: 
10.1111/j.1572-0241.2008.02028.x]
33 Liese AD, Liu L, Davis C, Standiford D, Waitzfelder B, Dabelea 
D, Bell R, Williams D, Imperatore G, Lawrence JM. Participation 
in pediatric epidemiologic research: the SEARCH for Diabetes in 
Youth Study experience. Contemp Clin Trials 2008; 29: 829-836 
[PMID: 18573350 DOI: 10.1016/j.cct.2008.05.008]
34 Drews KL, Harrell JS, Thompson D, Mazzuto SL, Ford EG, 
Carter M, Ford DA, Yin Z, Jessup AN, Roullet JB. Recruitment 
and retention strategies and methods in the HEALTHY study. Int J 
Obes (Lond) 2009; 33 Suppl 4: S21-S28 [PMID: 19623184 DOI: 
10.1038/ijo.2009.113.2758033]
35 Rhee H, Ciurzynski SM, Yoos HL. Pearls and pitfalls of community-
based group interventions for adolescents: lessons learned from an 
adolescent asthma cAMP study. Issues Compr Pediatr Nurs 2008; 31: 
122-135 [PMID: 18728958 DOI: 10.1080/01460860802272888.2565
511]
36 Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, 
Wilfley D. Treatment options for type 2 diabetes in adolescents and 
youth: a study of the comparative efficacy of metformin alone or in 
combination with rosiglitazone or lifestyle intervention in adolescents 
with type 2 diabetes. Pediatr Diabetes 2007; 8: 74-87 [PMID: 
17448130 DOI: 10.1111/j.1399-5448.2007.00237.x.2752327]
37 Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, 
Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle 
L, Tamborlane W, Willi S. Characteristics of adolescents and youth 
with recent-onset type 2 diabetes: the TODAY cohort at baseline. J 
Clin Endocrinol Metab 2011; 96: 159-167 [PMID: 20962021 DOI: 
10.1210/jc.2010-1642]
38 Petitti DB, Klingensmith GJ, Bell RA, Andrews JS, Dabelea D, 
Imperatore G, Marcovina S, Pihoker C, Standiford D, Waitzfelder 
B, Mayer-Davis E. Glycemic control in youth with diabetes: 
the SEARCH for diabetes in Youth Study. J Pediatr 2009; 155: 
668-672.e1-3 [PMID: 19643434 DOI: 10.1016/j.jpeds.2009.05.025]
39 Brawner BM, Volpe EM, Stewart JM, Gomes MM. Attitudes 
and beliefs toward biobehavioural research participation: voices 
and concerns of urban adolescent females receiving outpatient 
mental health treatment. Ann Hum Biol 2013; 40: 485-495 [PMID: 
23822716 DOI: 10.3109/03014460.2013.806590]
40 Braunstein JB, Sherber NS, Schulman SP, Ding EL, Powe NR. Race, 
medical researcher distrust, perceived harm, and willingness to participate 
in cardiovascular prevention trials. Medicine (Baltimore) 2008; 87: 1-9 
[PMID: 18204365 DOI: 10.1097/MD.0b013e3181625d78]
41 Koopmans B, Nielen MM, Schellevis FG, Korevaar JC. Non-
participation in population-based disease prevention programs 
in general practice. BMC Public Health 2012; 12: 856 [PMID: 
23046688 DOI: 10.1186/1471-2458-12-856.3490995]
42 Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S. 
Lifecourse epidemiology and molecular pathological epidemiology. 
Am J Prev Med 2015; 48: 116-119 [PMID: 25528613 DOI: 10.1016/
j.amepre.2014.09.031.4274745]
43 Ogino S, King EE, Beck AH, Sherman ME, Milner DA, 
Giovannucci E. Interdisciplinary education to integrate pathology 
and epidemiology: towards molecular and population-level health 
science. Am J Epidemiol 2012; 176: 659-667 [PMID: 22935517 
DOI: 10.1093/aje/kws226.3571252]
44 Hood KK, Lawrence JM, Anderson A, Bell R, Dabelea D, Daniels 
S, Rodriguez B, Dolan LM. Metabolic and inflammatory links 
to depression in youth with diabetes. Diabetes Care 2012; 35: 
2443-2446 [PMID: 23033243 DOI: 10.2337/dc11-2329.3507554]
45 Griffin JA, Gilliland SS, Perez G, Upson D, Carter JS. Challenges 
to participating in a lifestyle intervention program: the Native 
American Diabetes Project. Diabetes Educ 2000; 26: 681-689 
[PMID: 11140076]
46 Long JA, Jahnle EC, Richardson DM, Loewenstein G, Volpp KG. 
Peer mentoring and financial incentives to improve glucose control 
in African American veterans: a randomized trial. Ann Intern Med 
2012; 156: 416-424 [PMID: 22431674 DOI: 10.7326/0003-4819-1
56-6-201203200-00004.3475415]
47 Cuffee YL, Hargraves JL, Rosal M, Briesacher BA, Schoenthaler 
A, Person S, Hullett S, Allison J. Reported racial discrimination, 
trust in physicians, and medication adherence among inner-city 
African Americans with hypertension. Am J Public Health 2013; 
103: e55-e62 [PMID: 24028222 DOI: 10.2105/AJPH.2013.301554]
48 O’Brien SH, Holubkov R, Reis EC. Identification, evaluation, 
and management of obesity in an academic primary care center. 
Pediatrics 2004; 114: e154-e159 [PMID: 15286251]
49 Trauth JM, Musa D, Siminoff L, Jewell IK, Ricci E. Public 
attitudes regarding willingness to participate in medical research 
studies. J Health Soc Policy 2000; 12: 23-43 [PMID: 11184441 
DOI: 10.1300/J045v12n02_02]
P- Reviewer: Gómez-Sáez J, Ogino S    S- Editor: Ji FF    L- Editor: A 
E- Editor: Lu YJ 
1362 December 25, 2015|Volume 6|Issue 18|WJD|www.wjgnet.com
Sylvetsky AC et al . Buddies for adolescents with diabetes
                                      © 2015 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
